Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 26 · below the Ichimoku cloud · RSI 26 (oversold) · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in INBS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INBS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 17, 2026 | Sakiris Spiro KevinChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Mar 17, 2026 | Hurd Jonathan SDirector | Stock Award(Grant) at price 0.00 per share. | 5K | — |
| Mar 17, 2026 | Simeonidis HarryChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 30.5K | — |
| Mar 17, 2026 | Boyages Steven ConstantineDirector | Stock Award(Grant) at price 0.00 per share. | 5K | — |
| Mar 17, 2026 | Isenberg JasonDirector | Stock Award(Grant) at price 0.00 per share. | 5K | — |
| Mar 17, 2026 | Fraser Nicola MarionDirector | Stock Award(Grant) at price 0.00 per share. | 5K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.8 | -48.2 | -25.7 | -26.8 | 4.9 | -10.7 | -21.1 | 32.6 | -30.4 | -11.4 | −84.5% | ||
| 2025 | 25.7 | 22.7 | -33.3 | -11.1 | 10.2 | 22.0 | -8.1 | 2.5 | -37.0 | -4.2 | -32.4 | 44.4 | −31.9% |
| 2024 | -38.4 | 100.0 | -15.6 | -36.3 | -12.6 | -18.3 | -26.7 | 0.2 | 22.7 | -21.4 | 17.6 | -12.5 | −65.5% |
| 2023 | 324.5 | -64.1 | -52.5 | -17.2 | 13.8 | 1.8 | -35.3 | -2.2 | -41.5 | -79.0 | 94.4 | -19.5 | −91.5% |
| 2022 | -35.2 | -50.5 | 70.0 | -21.6 | -5.4 | 14.1 | 8.3 | -11.4 | -33.9 | 4.8 | -19.1 | -43.8 | −86.1% |
| 2021 | 2.0 | -20.8 | -5.5 | -30.1 | -23.8 | 30.9 | -17.8 | 0.0 | -22.2 | -19.0 | -2.9 | -27.5 | −80.6% |
| 2020 | — |
Buy / hold / sell counts
Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.